<?xml version="1.0" encoding="UTF-8"?>
<p id="par0220">Trametinib (
 <bold>91</bold>), selumetinib (
 <bold>92</bold>), everolimus, rapamycin, dasatinib, and imatinib are examples of inhibitors of kinase signaling pathways, which are active against SARS-CoV and MERS-CoV (see, for representative example 
 <bold>91</bold>, 
 <bold>92</bold> in 
 <xref rid="fig0065" ref-type="fig">Fig. 13</xref>). Their mechanism of action is to block the ABL1, ERK-MAPK and/or PI3K-AKT-mTOR pathways, which may block early viral entry and/or postentry events. However, the major drawback of the inhibitors may be associated with immunopathology 
 <xref rid="bib0725" ref-type="bibr">145</xref>, 
 <xref rid="bib0730" ref-type="bibr">146</xref>.
</p>
